^
    9ms
    Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial. (PubMed, Signal Transduct Target Ther)
    HA121-28 showed encouraging efficacy in advanced RET fusion NSCLC and its toxicity was tolerable in most patients. Nevertheless, cardiotoxicity is a notable concern that warrants careful attention.
    P1/2 data • PK/PD data • Journal
    |
    RET (Ret Proto-Oncogene) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    RET fusion • RET positive
    |
    HA121-28
    over3years
    Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=83, Recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    HA121-28
    almost4years
    Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=83, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Initiation date: Nov 2021 --> Mar 2022 | Trial primary completion date: Mar 2023 --> Oct 2023
    Trial initiation date • Trial primary completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    HA121-28
    4years
    Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=83, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
    Clinical • New P2 trial
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion
    |
    HA121-28